LLY - AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments | Benzinga
Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.
The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion’s closing market price of $10.64 on March 18, 2024.
Related Content: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Says AstraZeneca Is Favorably Positioned.
Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion.
AstraZeneca will acquire ...